BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8098976)

  • 1. A novel insertional mutation at the third zinc finger coding region of the WT1 gene in Denys-Drash syndrome.
    Ogawa O; Eccles MR; Yun K; Mueller RF; Holdaway MD; Reeve AE
    Hum Mol Genet; 1993 Feb; 2(2):203-4. PubMed ID: 8098976
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene.
    Köhler B; Schumacher V; Schulte-Overberg U; Biewald W; Lennert T; l'Allemand D; Royer-Pokora B; Grüters A
    Pediatr Res; 1999 Feb; 45(2):187-90. PubMed ID: 10022588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation.
    Machin GA
    Birth Defects Orig Artic Ser; 1996; 30(1):269-86. PubMed ID: 9125334
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Molecular genetic analysis of the WT1 gene in patients suspected to have the Denys-Drash syndrome".
    Coppes MJ; Clericuzio CL
    Med Pediatr Oncol; 1994; 23(4):390. PubMed ID: 8093189
    [No Abstract]   [Full Text] [Related]  

  • 6. A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
    Akasaka Y; Kikuchi H; Nagai T; Hiraoka N; Kato S; Hata J
    FEBS Lett; 1993 Feb; 317(1-2):39-43. PubMed ID: 8381368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
    Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
    Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
    Bardeesy N; Zabel B; Schmitt K; Pelletier J
    Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
    [No Abstract]   [Full Text] [Related]  

  • 9. A newly identified exonic mutation of the WT1 gene in a patient with Denys-Drash syndrome.
    Tsuda M; Sakiyama T; Owada M; Chiba Y
    Acta Paediatr Jpn; 1996 Jun; 38(3):265-6. PubMed ID: 8741319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel zinc finger mutation in a patient with Denys-Drash syndrome.
    Baird PN; Cowell JK
    Hum Mol Genet; 1993 Dec; 2(12):2193-4. PubMed ID: 8111391
    [No Abstract]   [Full Text] [Related]  

  • 11. WT1 mutations in patients with Denys-Drash syndrome: a novel mutation in exon 8 and paternal allele origin.
    Nordenskjöld A; Friedman E; Anvret M
    Hum Genet; 1994 Feb; 93(2):115-20. PubMed ID: 8112732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms' tumor) in a patient with Denys-Drash syndrome.
    Sakai A; Tadokoro K; Yanagisawa H; Nagafuchi S; Hoshikawa N; Suzuki T; Kohsaka T; Hasegawa T; Nakahori Y; Yamada M
    Hum Mol Genet; 1993 Nov; 2(11):1969-70. PubMed ID: 8281164
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
    Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
    Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel WT1 gene mutation p.H377N associated to Denys-Drash syndrome.
    Guaragna MS; Soardi FC; Assumpção JG; Zambaldi Lde J; Cardinalli IA; Yunes JA; de Mello MP; Brandalise SR; Aguiar Sdos S
    J Pediatr Hematol Oncol; 2010 Aug; 32(6):486-8. PubMed ID: 20562648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further evidence that imbalance of WT1 isoforms may be involved in Denys-Drash syndrome.
    König A; Jakubiczka S; Wieacker P; Schlösser HW; Gessler M
    Hum Mol Genet; 1993 Nov; 2(11):1967-8. PubMed ID: 8281163
    [No Abstract]   [Full Text] [Related]  

  • 16. Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1.
    Coppes MJ; Huff V; Pelletier J
    J Pediatr; 1993 Nov; 123(5):673-8. PubMed ID: 8229473
    [No Abstract]   [Full Text] [Related]  

  • 17. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
    Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
    Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms' tumour: reconciling genetics and biology.
    Van Heyningen V; Hastie ND
    Trends Genet; 1992 Jan; 8(1):16-21. PubMed ID: 1369730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 mutations may be a cause of severe renal failure due to nephroblastomatosis in Wilms' tumor patients.
    Santín S; Fraga G; Ruíz P; Pardo N; Torrent M; Martí T; Ballarín J; Ars E; Torra R
    Clin Nephrol; 2011 Sep; 76(3):244-8. PubMed ID: 21888862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.